Harbor is an AI-native contract research organization (CRO) for clinical trial operations. It began as an AI-enabled electronic data capture system and has expanded into full-service trial execution, automating workflows such as study design, data capture, query generation, monitoring, and database management. By building on its proprietary system of record, Harbor delivers the regulated services companies traditionally buy from legacy CROs while reducing manual labor and accelerating timelines. The company was founded by Albert Cai (CEO), previously in clinical trials and regulatory strategy at Biolinq, and Nathan H. Leung (CTO), a former Google and Ramp engineer; it is part of Y Combinator's Spring 2026 batch.